{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-021832","form_type":"8-K","ticker":"MNPR","cik":"0001645469","company_name":"Monopar Therapeutics","filed_at":"2026-06-26T20:06:18+00:00","discovered_at":"2026-06-26T20:07:01.437497+00:00","generated_at":"2026-06-26T20:07:47.090721+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Monopar reports ALXN1840 shows significant neurologic and global benefit in Phase 3 FoCus trial","bullets":["ALXN1840 achieved significant neurologic improvement on UWDRS Part III (p=0.006) vs SOC (p=0.435) over 48 weeks.","Global clinical improvement on CGI-I at Week 48 significantly greater with ALXN1840 vs SOC (p<0.001).","Favorable safety profile: drug-related SAEs in 4.9% of patients, no treatment-related deaths.","Results support planned NDA submission to FDA for ALXN1840 in mid-2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-021832","json":"https://secwatch.observer/filing/0001437749-26-021832.json","markdown":"https://secwatch.observer/filing/0001437749-26-021832.md","text":"https://secwatch.observer/filing/0001437749-26-021832.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645469/000143774926021832/0001437749-26-021832-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645469/000143774926021832/mnpr20260625_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T20:07:47.090721+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}